We considered that the significantly differential metabolites (hydroxykynurenine, erythritol, carnosine, and choline) and proteins (SELENBP1, ENPP1, CAMK2D, and ABCA8) may be potential targets or novel biomarkers of CAVD and thus serve as the foundation for further investigation of CAVD. This evidence concerns the gene SELENBP1 and congenital bilateral aplasia of vas deferens from CFTR mutation.